These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22440750)

  • 1. Long-distance correlations of rhinovirus capsid dynamics contribute to uncoating and antiviral activity.
    Roy A; Post CB
    Proc Natl Acad Sci U S A; 2012 Apr; 109(14):5271-6. PubMed ID: 22440750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics simulations of human rhinovirus and an antiviral compound.
    Speelman B; Brooks BR; Post CB
    Biophys J; 2001 Jan; 80(1):121-9. PubMed ID: 11159387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle.
    Hadfield AT; Lee Wm; Zhao R; Oliveira MA; Minor I; Rueckert RR; Rossmann MG
    Structure; 1997 Mar; 5(3):427-41. PubMed ID: 9083115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral agent blocks breathing of the common cold virus.
    Lewis JK; Bothner B; Smith TJ; Siuzdak G
    Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6774-8. PubMed ID: 9618488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of an antiviral compound from the internal pocket of human rhinovirus 14 capsid.
    Li Y; Zhou Z; Post CB
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7529-34. PubMed ID: 15899980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VP4 protein from human rhinovirus 14 is released by pressure and locked in the capsid by the antiviral compound WIN.
    Gonçalves RB; Mendes YS; Soares MR; Katpally U; Smith TJ; Silva JL; Oliveira AC
    J Mol Biol; 2007 Feb; 366(1):295-306. PubMed ID: 17161425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.
    Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC
    J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Determinants of Human Rhinovirus Infection, Assembly, and Conformational Stability at Capsid Protein Interfaces.
    Valiente L; López-Argüello S; Rodríguez-Huete A; Valbuena A; Mateu MG
    J Virol; 2022 Dec; 96(23):e0084022. PubMed ID: 36374110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural analysis of antiviral agents that interact with the capsid of human rhinoviruses.
    Badger J; Minor I; Oliveira MA; Smith TJ; Rossmann MG
    Proteins; 1989; 6(1):1-19. PubMed ID: 2558377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryoelectron microscopy analysis of the structural changes associated with human rhinovirus type 14 uncoating.
    Hewat EA; Blaas D
    J Virol; 2004 Mar; 78(6):2935-42. PubMed ID: 14990711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity.
    Rosenwirth B; Oren DA; Arnold E; Kis ZL; Eggers HJ
    Antiviral Res; 1995 Jan; 26(1):65-82. PubMed ID: 7741522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel basis of capsid stabilization by antiviral compounds.
    Phelps DK; Post CB
    J Mol Biol; 1995 Dec; 254(4):544-51. PubMed ID: 7500332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human rhinovirus 14 complexed with fragments of active antiviral compounds.
    Bibler-Muckelbauer JK; Kremer MJ; Rossmann MG; Diana GD; Dutko FJ; Pevear DC; McKinlay MA
    Virology; 1994 Jul; 202(1):360-9. PubMed ID: 8009848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
    Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
    J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules.
    Shih SR; Chen SJ; Hakimelahi GH; Liu HJ; Tseng CT; Shia KS
    Med Res Rev; 2004 Jul; 24(4):449-74. PubMed ID: 15170592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhinovirus-mediated endosomal release of transfection complexes.
    Zauner W; Blaas D; Kuechler E; Wagner E
    J Virol; 1995 Feb; 69(2):1085-92. PubMed ID: 7815487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
    Dewindt B; van Eemeren K; Andries K
    Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating.
    Smith TJ; Kremer MJ; Luo M; Vriend G; Arnold E; Kamer G; Rossmann MG; McKinlay MA; Diana GD; Otto MJ
    Science; 1986 Sep; 233(4770):1286-93. PubMed ID: 3018924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions.
    Mosser AG; Sgro JY; Rueckert RR
    J Virol; 1994 Dec; 68(12):8193-201. PubMed ID: 7966611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the structure of a common cold virus, human rhinovirus 14, refined at a resolution of 3.0 A.
    Arnold E; Rossmann MG
    J Mol Biol; 1990 Feb; 211(4):763-801. PubMed ID: 2156077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.